Neurotrophic factors: Basis for their clinical application;Factores neurotróficos: Fundamentos para su aplicación clínica

Neurologia

Volumn 18, Issue 1, 2003, Pages 18-28

  Morís, Germán ^a   Vega, J A ^b  

^a HOSPITAL ÁLVAREZ BUYLLA   (Spain)

^b UNIVERSITY OF OVIEDO   (Spain)

Author keywords

CNTF; GDNF; IGF 1; Neurodegererative diseases; Neurotrophic factors; NFG

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CILIARY NEUROTROPHIC FACTOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; NERVE GROWTH FACTOR; NEUROTROPHIC FACTOR; NEUROTROPHIN 3; SOMATOMEDIN;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM; DEGENERATIVE DISEASE; GLIA CELL; HUMAN; NERVE CELL; NERVE CELL PLASTICITY; PARKINSON DISEASE; PERIPHERAL NEUROPATHY; REVIEW;

ANIMALS; BRAIN INJURIES; CLINICAL TRIALS; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HUMANS; NERVE GROWTH FACTORS; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; SOMATOMEDINS;

EID: 17144469657     PISSN: 02134853     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (113)

1. Terenghi G. Peripheral nerve regenaration and neurotrophic factors. J Anat 1999;194:1-14.
2. Yuen EC. The role of neurotrophic factors in disorders of peripheral nerves and motor neurons. Phys Med Rehabil Clin N Am 2001;12:293-306.
3. Bradshaw RA, Blundell TL, Lapatto R, McDonald NQ, Murray-Rust J. Nerve Growth Factor revisited. Trends Biochem Sci 1993;18:48-52.
4. Henderson CE, Phillips HS, Pollock RA, Davies AM, Lemeulle C, Armanini M, et al. GDNF: a potent survival factor for motoneurons present in peripheral nerve and muscle. Science 1994;266:1062-4.
5. Snider WD, Elliott JL, Yan Q. Axotomy-induced neuronal death during development. J Neurobiol 1992;23:1231-46.
6. Maisonpierre PC, Belluscio L, Friedman B, Alderson RF, Wiegand SJ, Furth ME, et al. NT3, BDNF, and NGF in the developing rat nervous system: parallel as well as reciprocal patterns of expression. Neuron 1990;5:501-9.
7. Davies AM. The emerging generality of the neurotrophic hypothesis. Trends Neurosci 1988;11:243-4.
8. Oppenheim RW. Neurotrophic survival molecules for motoneurons: a embarrasment of riches. Neuron 1996;17:195-7.
9. Robertson GS, Crocker SJ, Nicholson DW, Schulz JB. Neuroprotection by the inhibition of apoptosis. Brain Pathol 2000;10:283-92.
10. Levi-Montalcini L. Selective growth-stimulating effects of mouse sarcomas on the sensory and sympathetic nervous sensory chick embryos. J Exp Zool 1951;116:321-6.
11. Levi-Montalcini R. The nerve growth factor: thirty-five years later. Science 1987;237:1154-62.
12. Huang EJ, Reichardt LF. Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci 2001;24:677-736.
13. Fariñas I, Cano-Jaimez M, Bellmunt E, Soriano M. Regulation of neurogenesis by neurotrophins in developing spinal sensory ganglia. Brain Res Bull 2002;57:809-16.
14. Barbacid M. The trk family of neurotrophin receptors. J Neurobiol 1994;25:1386-403.
15. Neet KE, Campenot RB. Receptor binding, internalization, and retrograde transport of neurotrophic factors. Cell Mol Life Sci 2001;58:1021-35.
16. Ernfors P. Local and target-derived actions of neurotrophins during peripheral nervous system development. Cell Mol Life Sci 2001;58:1036-44.
17. Klein R, Lamballe F, Bryant S, Barbacid M. The trkB tyrosine kinase is a receptor for neurotrophin-4. Neuron 1992;8:947-56.
18. Fariñas I. Neurotrophin actions during the development of the peripheral nervous system. Microsc Res Tech 1999;45:233-42.
19. Chao MV, Hempstead BL. p75 and trk: a two receptor system. Trends Neurosci 1995;18:321-6.
20. Carter BD, Lewin GR. Neurotrophins live or let die: does p75NTR decide? Neuron 1997;18:187-190.
21. Hempstead BL. The many faces of p75(NTR). Curr Opin Neurobiol 2002;12:260-7.
22. Lee FS, Kim AH, Khursigara G, Chao MV. The uniqueness of being a neurotrophin receptor. Curr Opin Neurobiol 2001;11:281-6.
23. Airaksinen MS, Titievsky A, Saarma M. GDNF family neurotrophic factor signalling: four masters, one servant? Moll Cell Neurosci 1999;13:313-25.
24. Lin L-FH, Doherty DH, Lile JD, Bektesh S, Collins F. GDNF: A glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 1993;260:1130-2.
25. Eigenbrot C, Gerber N. X-ray structure of glial cell-derived neurotrophic factor at 1.9 Å resolution and implications for receptor binding. Nat Struc Biol 1997;4:435-8.
26. Saarma M, Sariola H. Other neurotrophic factors: Glial cell line-derived neurotrophic factor (GDNF). Microsc Res Tech 1999;45:92-302
27. Nosrat CA, Tomac A, Lindqvist E, Lindskog S, Humpel C, Stromberg I, et al. Cellular expression of GDNF mRNA suggests multiple functions inside and outside the nervous system. Cell Tissue Res 1996;286:191-207.
28. Jongen JLM, Dalm E, Vecht CJ, Holstege JC. Depletion of GDNF from primary afferents in adult rat dorsal horn following peripheral axotomy. NeuroReport 1999;10:867-71.
29. Neff NT, Prevette D, Houenou LJ, Lewis ME, Glicksman MA, Yin QW, et al. Insulin-like growth factors: putative muscle-derived trophic agents that promote motoneuron survival. J Neurobiol 1993;24:1578-88.
30. Li L, Oppenheim RW, Lei M, Houenou LJ. Neurotrophic agents prevent motoneuron death following sciatic nerve section in the neonatal mouse. J Neurobiol 1994;25:759-66.
31. Ishii DN, Lupien SB. Insulin-like growth factors protect against diabetic neuropathy: effects on sensory nerve regeneration in rats. J Neurosci Res 1995;40:138-44.
32. Friedman B, Scherer SS, Rudge JS, Helgren M, Morrisey D, McClain J, et al. Regulation of cilliary neurotrophic factor expression in myelin-related Schwan cells in vivo. Neuron 1992;9:295-305.
33. Rende M, Muir D, Ruoslahti E, Hagg T, Varon S, Manthorpe M. Immunolocalisation of cilliary neurotrophic factor in adult rat sciatic nerve. Glia 1992;5:25-32.9.
34. Davis S, Aldrich TH, Valenzuela DM, Wong W, Furth ME, Squinto SP, et al. The receptor for cilliary neurotrophic factor. Science 1991;253:59-63.
35. Ip NY, Yancopoulos G. Cilliary neurotrophic factor and its receptor complex. Progress Growth Factor Res 1992;4:139-55.
36. Richardson PM. Cilliary neurotrophic factor: a review. Pharmacol Therapy 1994;63:187-98.
37. Coyle JT, Price DL, DeLong MR. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science 1983;219:1184-90.
38. Hefti F. Nerve growth factor promotes survival of septal cholinergic neurons after fimbrial transections. J Neurosci 1986;6:2155-62.
39. Williams LR, Varon S, Peterson GM, Wictorin K, Fischer W, Bjorklund A, et al. Continuous infusion of nerve growth factor prevents basal forebrain neuronal death after fimbria fornix transection. Proc Natl Acad Sci U S A 1986;83:9231-5.
40. Fischer W, Wictorin K, Bjorklund A, Williams LR, Varon S, Gage FH. Amelioration of cholinergic neuron atrophy and spatial memory impairment in aged rats by nerve growth factor. Nature 1987;329:65-8.
41. Kromer LF. Nerve growth factor treatment after brain injury prevents neuronal death. Science 1987;235:214-6.
42. Ogawa S, Nabeshima T, Kameyama T, Hayashi K. Effects of nerve growth factor (NGF) in rats with basal forebrain lesions. Jpn J Pharmacol 1993;61:141-4.
43. Nabeshima T, Yamada K. Neurotrophic factor strategies for the treatment of Alzheimer disease. Alzheimer Dis Assoc Disord 2000;14 (Suppl 1):39-46.
44. Allen SJ, MacGowan SH, Treanor JJ, Feeney R, Wilcock GK, Dawbarn D. Normal beta-NGF content in Alzheimer's disease cerebral cortex and hippocampus. Neurosci Lett 1991;131:135-9.
45. Murase K, Nabeshima T, Robitaille Y, Quirion R, Ogawa M, Hayashi K. NGF level of is not decreased in the serum, brain-spinal fluid, hippocampus, or parietal cortex of individuals with Alzheimer's disease. Biochem Biophys Res Commun 1993;193:198-203.
46. Jette N, Cole MS, Fahnestock M. NGF mRNA is not decreased in frontal cortex from Alzheimer's disease patients. Brain Res Mol Brain Res 1994;25:242-50.
47. Crutcher KA, Scott SA, Liang S, Everson WV, Weingartner J. Detection of NGF-like activity in human brain tissue: increased levels in Alzheimer's disease. J Neurosci 1993;13:2540-50.
48. Scott SA, Mufson EJ, Weingartner JA, Skau KA, Crutcher KA. Nerve growth factor in Alzheimer's disease: increased levels throughout the brain coupled with declines in nucleus basalis. J Neurosci 1995;15:6213-21.
49. Salehi A, Verhaagen J, Dijkhuizen PA, Swaab DF. Co-localization of high-affinity neurotrophin receptors in nucleus basalis of Meynert neurons and their differential reduction in Alzheimer's disease. Neuroscience 1996;75:373-87.
50. Boissiere F, Faucheux B, Ruberg M, Agid Y, Hirsch EC. Decreased TrkA gene expression in cholinergic neurons of the striatum and basal forebrain of patients with Alzheimer's disease. Exp Neurol 1997;145:245-52.
51. Mufson EJ, Lavine N, Jaffar S, Kordower JH, Quirion R, Saragovi HU. Reduction in p140-TrkA receptor protein within the nucleus basalis and cortex in Alzheimer's disease. Exp Neurol 1997;146:91-103.
52. Narisawa-Saito M, Wakabayashi K, Tsuji S, Takahashi H, Nawa H. Regional specificity of alterations in NGF, BDNF and NT-3 levels in Alzheimer's disease. Neuroreport 1996;7:2925-8.
53. Phillips HS, Hains JM, Armanini M, Laramee GR, Johnson SA, Winslow JW. BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease. Neuron 1991;7:695-702.
54. Connor B, Beilharz EJ, Williams C, Synek B, Gluckman PD, Faull RL, et al. Insulin-like growth factor-I (IGF-I) immunoreactivity in the Alzheimer's disease temporal cortex and hippocampus. Brain Res Mol Brain Res 1997;49:283-90.
55. Mustafa A, Lannfelt L, Lilius L, Islam A, Winblad B, Adem A. Decreased plasma insulin-like growth factor-I level in familial Alzheimer's disease patients carrying the Swedish APP 670/671 mutation. Dement Geriatr Cogn Disord 1999;10:446-51
56. Guo Q, Sebastian L, Sopher BL, Miller MW, Glazner GW, Ware CB, et al. Neurotrophic factors [activity-dependent neurotrophic factor (ADNF) and basic fibroblast growth factor (bFGF)] interrupt excitotoxic neurodegenerative cascades promoted by a PS1 mutation. Proc Natl Acad Sci U S A 1999;96:4125-30.
57. Olson L, Nordberg A, von Holst H, Backman L, Ebendal T, Alafuzoff I, et al. Nerve growth factor affects 11C-nicotine binding, blood flow, EEG, and verbal episodic memory in an Alzheimer patient (case report). J Neural Transm Park Dis Dement Sect 1992;4:79-95.
58. Seiger A, Nordberg A, von Holst H, Backman L, Ebendal T, Alafuzoff I, et al. Intracranial infusion of purified nerve growth factor to an Alzheimer patient: the first attempt of a possible future treatment strategy. Behav Brain Res 1993;57:255-61.
59. Eriksdotter Jonhagen M, Nordberg A, Amberla K, Backman L, Ebendal T, Meyerson B, et al. Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. Dement Geriatr Cogn Disord 1998;9:246-57.
60. Hoffer BJ, Hoffman A, Bowenkamp K, Huettl P, Hudson J, Martin D, et al. Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo. Neurosci Lett 1994;182:107-11.
61. Winkler C, Sauer H, Lee CS, Bjorklund A. Short-term GDNF treatment provides long-term rescue of lesioned nigral dopaminergic neurons in a rat model of Parkinson's disease. J Neurosci 1996;16:7206-15.
62. Tomac A, Lindqvist E, Lin LF, Ogren SO, Young D, Hoffer BJ, et al. Protection and repair of the nigrostriatal dopaminergic sytem by GDNF in vivo. Nature 1995;373:335-9.
63. Beck KD, Valverde J, Alexi T, Poulsen K, Moffat B, Vandlen RA, et al. Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain. Nature 1995;373:339-41.
64. Chauhan NB, Siegel GJ, Lee JM. Depletion of glial cell line-derived neurotrophic factor in substantia nigra neurons of Parkinson's disease brain. J Chem Neuroanat 2001;21:277-88.
65. Wartiovaara K, Hytonen M, Vuori M, Rinne J, Sariola H. Mutations analisis of the glial cell line-derived neurotrophic factor gene in Parkinson's disease. Exp Neurol 1998;152:307-9.
66. Kordower JH, Palfi S, Chen EY, Ma SY, Sendera T, Cochran EJ, et al. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann Neurol 1999;46:419-24.
67. Mendez I, Dagher A, Hong M, Hebb A, Gaudet P, Law A, et al. Enhancement of survival of stored dopaminergic cells and promotion of graft survival by exposure of human fetal nigral tissue to glial cell line-derived neurotrophic factor in patients with Parkinson's disease. Report of two cases and technical considerations. J Neurosurg 2000;92:863-9.
68. Mayor S. New treatment improves symptoms of Parkinson's disease. BMJ 2002;324:997.
69. Perez-Navarro E, Canudas AM, Akerund P, Alberch J, Arenas E. Brain-derived neurotrophic factor, neurotrophin-3, and neurotrophin-4/5 prevent the death of striatal projection neurons in a rodent model of Huntington's disease. J Neurochem 2000;75:2190-9.
70. Anderson KD, Panayotatos N, Corcoran TL, Lindsay RM, Wiegand SJ. Ciliary neurotrophic factor protects striatal output neurons in an animal model of Huntington disease. Proc Natl Acad Sci U S A 1996;93:7346-51.
71. Bachoud-Levi AC, Deglon N, Nguyen JP, Bloch J, Bourdet C, Winkel L, et al. Neuroprotective gene therapy for Huntington's disease using a polymer encapsulated BHK cell line engineered to secrete human CNTF. Hum Gene Ther 2000;11:1723-9.
72. Kato T, Nakano S, Kogure K, Sasaki H, Koiwai K, Yamasaki Y, et al. The binding of basic fibroblast growth factor to ischaemic neurons in the rat. Neuropathol Appl Neurobiol 1992;18:282-90.
73. Comelli MC, Guidolin D, Seren MS, Zanoni R, Canella R, Rubini R, et al. Time course, localization and pharmacological modulation of immediate early inducible genes, brain-derived neurotrophic factor and trkB messenger RNAs in the rat brain following photochemical stroke. Neuroscience 1993;55:473-90.
74. Humpel C, Hoffer B, Stromberg I, Bektesh S, Collins F, Olson L. Neurons of the hippocampal formation express glial cell line-derived neurotrophic factor messenger RNA in response to kainate-induced excitation. Neuroscience 1994;59:791-5.
75. Zhang ZG, Zhang L, Jiang Q, Zhang R, Davies K, Powers C, et al. VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain. J Clin Invest 2000;106:829-38.
76. Pleasure D, Bannerman P, Ara J, Scarlato M, Itoh T. Prospects for vascular endothelial growth factor neurotherapeutics. Arch Neurol 2002;59:692-4.
77. Yamashita K, Wiessner C, Lindholm D, Thoenen H, Hossmann KA. Post-occlusion treatment with BDNF reduces infarct size in a model of permanent occlusion of the middle cerebral artery in rat. Metab Brain Dis 1997;12:271-80.
78. Mocchetti I, Wrathall JR. Neurotrophic factors in central nervous system trauma. J Neurotrauma 1995;12:853-70.
79. Jones LL, Oudega M, Bunge MB, Tuszynski MH. Neurotrophic factors, cellular bridges and gene therapy for spinal cord injury. J Physiol 2001;533:83-9.
80. Lu P, Blesch A, Tuszynski MH. Neurotrophism without neurotropism: BDNF promotes survival but not growth of lesioned corticospinal neurons. J Comp Neurol 2001;436:456-70.
81. Riva MA, Mocchetti I. Developmental expression of the basic fibroblast growth factor gene in rat brain. Brain Res Dev Brain Res 1991;62:45-50.
82. Steeves JD, Tetzlaff W. Engines, accelerators, and brakes on functional spinal cord repair. Ann N Y Acad Sci 1998;860:412-24.
83. McDonald JW, Sadowsky C. Spinal-cord injury. Lancet 2002;359:417-25.
84. Brewster WJ, Fernyhough P, Diemel LT, Mohiuddin L, Tomlinson DR. Diabetic neuropathy, nerve growth factor and other neurotrophic factors. Trends Neurosci 1994;17:321-5.
85. Anand P, Terenghi G, Warner G, Kopelman P, Williams-Chestnut RE, Sinicropi DV. The role of endogenous nerve growth factor in human diabetic neuropathy. Nat Med 1996;2:703-7.
86. Faradji V, Sotelo J. Low serum levels of nerve growth factor in diabetic neuropathy. Acta Neurol Scand 1990;81:402-6.
87. Diemel LT, Cai F, Anand P, Warner G, Kopelman PG, Fernyhough P, et al. Increased nerve growth factor mRNA in lateral calf skin biopsies from diabetic patients. Diabet Med 1999;16:113-8.
88. Yuen EC, Howe CL, Li Y, Holtzman DM, Mobley WC. Nerve growth factor and the neurotrophic factor hypothesis. Brain Dev 1996;18:362-8.
89. Apfel SC, Kessler JA, Adornato BT, Litchy WJ, Sanders C, Rask CA. Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. NGF Study Group. Neurology 1998;51:695-702.
90. Apfel SC, Schwartz S, Adornato BT, Freeman R, Biton V, Rendell M, et al. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: A randomized controlled trial. rhNGF Clinical Investigator Group. JAMA 2000;284:2215-21.
91. McArthur JC, Yiannoutsos C, Simpson DM, Adornato BT, Singer EJ, Hollander H, et al. A phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection. AIDS Clinical Trials Group Team 291. Neurology 2000;54:1080-8.
92. Mitsumoto H, Ikeda K, Klinkosz B, Cedarbaum JM, Wong V, Lindsay RM. Arrest of motor neuron disease in wobbler mice cotreated with CNTF and BDNF. Science 1994;265:1107-10.
93. Ikeda K, Klinkosz B, Greene T, Cedarbaum JM, Wong V, Lindsay RM, et al. Effects of brain-derived neurotrophic factor on motor dysfunction in wobbler mouse motor neuron disease. Ann Neurol 1995;37:505-11.
94. Bradley WG. A phase I/II study of recombinant brain-derived neurotrophic in patients with ALS (abstract). Ann Neurol 1995;38:971.
95. The BDNF Study Group (Phase III): A controlled trial of recombinant methionyl human BDNF in ALS. Neurology 1999;52:1427-33.
96. Ochs G, Penn RD, York M, Giess R, Beck M, Tonn J, et al. A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000;1:201-6.
97. Lai EC, Felice KJ, Festoff BW, Gawel MJ, Gelinas DF, Kratz R, et al. Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group. Neurology 1997;49:1621-30.
98. Borasio GD, Robberecht W, Leigh PN, Emile J, Guiloff RJ, Jerusalem F, et al. A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group. Neurology 1998;51:583-6.
99. Connolly AM, Pestronk A, Mehta S, Yee WC, Green BJ, Fellin C, et al. Serum IgM monoclonal autoantibody binding to the 301 to 314 amino acid epitope of beta-tubulin: clinical association with slowly progressive demyelinating polyneuropathy. Neurology 1997 Jan;48(1):243-8.
100. Sendtner M, Carroll P, Holtmann B, Hughes RA, Thoenen H. Ciliary neurotrophic factor. J Neurobiol 1994;25:1436-53.
101. Arakawa Y, Sendtner M, Thoenen H. Survival effect of cilliary neurotrophic factor (CNTF) on chick embryonic motoneurons in culture: comparision with other neurotrophic factors and cytokines. J Neurosci 1990;10:3507-15.
102. Mitsumoto H, Ikeda K, Holmlund T, Greene T, Cedarbaum JM, Wong V, et al. The effects of CNTF on motor dysfunction in wobbler mouse motor neuron disease. Ann Neurol 1994;36:142-8.
103. ALS CNTF Treatment Study Group. A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. Neurology 1996;46:1244-9.
104. Miller RG, Petajan JH, Bryan WW, Armon C, Barohn RJ, Goodpasture JC, et al. A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. rhCNTF ALS Study Group. Ann Neurol 1996;39:256-60.
105. Penn RD, Kroin JS, York MM, Cedarbaum JM. Intrathecal ciliary neurotrophic factor delivery for treatment of amyotrophic lateral sclerosis (phase I trial). Neurosurgery 1997;40:94-9.
106. Mitsumoto H, Tsuzaka K. Neurotrophic factors and neuromuscular disease: II. GDNF, other neurotrophic factors, and future directions. Muscle Nerve 1999;22:1000-21.
107. Apfel SC. Is the therapeutic application of neurotrophic factors dead? Ann Neurol 2002;51:8-11.
108. Thorne RG, Frey WH Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations. Clin Pharmacokinet 2001;40:907-46.
109. Chattopadhyay M, Wolfe D, Huang S, Goss J, Glorioso JC, Mata M, et al. In vivo gene therapy for pyridoxine-induced neuropathy by herpes simplex virus-mediated gene transfer of neurotrophin-3. Ann Neurol 2002;51:19-27.
110. Smith DE, Roberts J, Gage FH, Tuszynski MH. Age-associated neuronal atrophy occurs in the primate brain and is reversible by growth factor gene therapy. Proc Natl Acad Sci U S A 1999;96:10893-8.
111. Tuszynski MH, Roberts J, Senut MC, U HS, Gage FH. Gene therapy in the adult primate brain: intraparenchymal grafts of cells genetically modified to produce nerve growth factor prevent cholinergic neuronal degeneration. Gene Ther 1996;3:305-14.
112. Aebischer P, Schluep M, Deglon N, Joseph JM, Hirt L, Heyd B, et al. Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients. Nat Med 1996;2:696-9.
113. Apfel SC. Neurotrophic factor therapy: prospects and problems. Clin Chem Lab Med 2001;39:351-5.